文献速递消化系统肿瘤

RAS野生型转移性结直肠癌患者接受氟尿嘧啶和亚叶酸钙联合或不联合帕尼单抗维持治疗的健康相关生活质量:PanaMa(AIO KRK 0212)试验的预设二次分析

Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab as maintenance therapy: a prespecified secondary analysis of the PanaMa (AIO KRK 0212) trial.
PubMed 文献 · Eur J Cancer · 2023-06-28

PanaMa试验预设二次分析评估RAS野生型转移性结直肠癌患者维持治疗期间的健康相关生活质量(HRQOL)。诱导期多数维度稳定或改善,食欲减退和腹泻显著恶化;维持期HRQOL稳定,诱导期恶化的维度显著改善,两治疗组间无显著差异。结论认为维持治疗改善诱导期恶化的HRQOL维度,帕尼单抗联合FU/FA延长无进展生存期且不负面影响HRQOL。

要点

  • 诱导期多数HRQOL维度稳定或改善,食欲减退和腹泻显著恶化。
  • 维持期HRQOL稳定,诱导期恶化的维度显著改善,两组间无显著差异。
  • 帕尼单抗联合FU/FA维持治疗延长无进展生存期且不负面影响HRQOL。

核心结论

  • 维持治疗改善诱导期恶化的HRQOL维度,同时稳定其他维度。
  • RAS野生型转移性结直肠癌患者中,FU/FA联合帕尼单抗维持治疗延长无进展生存期且不负面影响HRQOL。

研究设计与样本

  • PanaMa(AIO KRK 0212)试验的预设二次分析,评估RAS野生型转移性结直肠癌患者HRQOL。
  • 使用EORTC QLQ-C30在每个治疗周期至疾病进展/死亡时评估HRQOL。
  • 诱导治疗期间完成至少一份HRQOL问卷的患者为349/377(93%)。
  • 随机并接受维持治疗的患者中完成至少一份HRQOL问卷者为237/248(96%)。
  • 比较分析分别按随机化状态和治疗组对诱导期和维持期进行。

主要发现

  • 诱导治疗期间,多数HRQOL维度保持稳定或改善,而食欲减退和腹泻显著恶化。
  • 维持治疗期间,HRQOL维度保持稳定,诱导期恶化的维度显著改善。
  • 维持治疗期间,治疗组间HRQOL无显著差异。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The PanaMa trial demonstrated significant benefit in progression-free survival with the addition of panitumumab (Pmab) to fluorouracil and folinic acid (FU/FA) as maintenance therapy following first-line induction therapy with FOLFOX/Pmab in patients with RAS wild-type metastatic colorectal cancer. Here, we report health-related quality of life (HRQOL) analyses from the PanaMa trial. METHODS: HRQOL outcomes were evaluated using European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) at every cycle of therapy until disease progression/death. HRQOL outcomes were mean and individual changes in EORTC QLQ-C30 from baselines (before induction therapy and before maintenance therapy) to each cycle of treatment. Comparative analyses were performed by randomisation status and treatment arm for induction- and maintenance-therapy, respectively. The trial is registered with clinicaltrials.gov (NCT01991873). RESULTS: At least one HRQOL questionnaire was completed by a total of 349/377 (93%) patients who received induction therapy, and by 237/248 (96%) patients who were randomised and received maintenance therapy. During induction therapy, most HRQOL dimensions remained stable or showed improvement, while appetite loss and diarrhoea significantly deteriorated. During maintenance therapy, HRQOL dimensions remained stable, while those that deteriorated during induction therapy showed significant improvement, without significant differences between the treatment arms. CONCLUSION: Maintenance therapy improves HRQOL dimensions that initially deteriorated during induction therapy while stabilising HRQOL in other dimensions. The addition of Pmab to FU/FA as maintenance therapy in patients with RAS wild-type metastatic colorectal cancer prolongs progression-free survival without negative impact on HRQOL.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Ballhausen A, Karthaus M, Fruehauf S, et al. Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab as maintenance therapy: a prespecified secondary analysis of the PanaMa (AIO KRK 0212) trial. Eur J Cancer. 2023. PMID: 37454537. doi:10.1016/j.ejca.2023.112955

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。